Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
April 08, 2024 07:00 ET
|
Marker Therapeutics
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada ...
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
March 25, 2024 17:45 ET
|
Marker Therapeutics
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 22, 2024 12:30 ET
|
Marker Therapeutics
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
January 22, 2024 07:30 ET
|
Marker Therapeutics
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
January 08, 2024 08:24 ET
|
Marker Therapeutics
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
December 21, 2023 11:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 11, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 17:00 ET
|
Marker Therapeutics
Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
September 11, 2023 07:00 ET
|
Marker Therapeutics
Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who...
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023 08:00 ET
|
Marker Therapeutics
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...